Business · 26/05/2026Updated: 10/17/2026 · 1 min read
FDA Renews Pulmonary-Allergy Drugs Advisory Committee for 2 Years
The FDA has renewed the Pulmonary-Allergy Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on May 30, 2028.
Original source language: Federal Register — Health and Human ServicesOpen original release →